Brief: Journey Medical Corporation Announces First Patient Dosed In Phase 3 Clinical Trial Evaluating Dfd-29 (Minocycline Modified Release Capsules 40 Mg) For The Treatment Of Rosacea
17/03/2022 13:50
March 17 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION ANNOUNCES FIRST PATIENT DOSED
IN
PHASE 3 CLINICAL TRIAL EVALUATING DFD-29 (MINOCYCLINE MODIFIED
RELEASE CAPSULES 40 MG) FOR THE TREATMENT OF ROSACEA
Source text for Eikon: ID:nGNX41b5Jr
Further company coverage: DERM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Journey Medical
See all newsJourney Medical Corp expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
U.S. STOCKS ON THE MOVE-Five Below, Salesforce, IBM, Akamai Technologies